Aleksandra Napieralska1, Sławomir Blamek1. 1. Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.
Abstract
BACKGROUND: The aim of the study was to assess the results of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy (SRS/SRT) for skull base chordomas. MATERIALS AND METHODS: Twenty-three patients aged 12-75 were treated with SRS/SRT due to skull base chordoma. In 19 patients SRS/SRT was a part of the primary therapy, while in 4, a part of the treatment of recurrence. In 4 patients SRS/SRT was used as a boost after conventional radiotherapy and in 19 cases it was the only irradiation method applied. Patients were irradiated to total dose of 6-35 Gy and median total equivalent dose of 52 Gy. RESULTS: During median follow-up of 39 months, 4 patients died. One-, two- and five-year OS was 95%, 89% and 69%, respectively. In nine patients, progression of the disease was diagnosed during study period. One-, two- and five-year progression free survival (PFS) from the end of radiotherapy was 81%, 59% and 43%, respectively. Radiotherapy was well tolerated and only two patients in our group experienced moderate treatment-related toxicity. CONCLUSION: SRS/SRT alone or in combination with surgery is a safe and effective method of irradiation of patients with skull base chordomas. High EQD2 is necessary to achieve satisfactory treatment results.
BACKGROUND: The aim of the study was to assess the results of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy (SRS/SRT) for skull base chordomas. MATERIALS AND METHODS: Twenty-three patients aged 12-75 were treated with SRS/SRT due to skull base chordoma. In 19 patients SRS/SRT was a part of the primary therapy, while in 4, a part of the treatment of recurrence. In 4 patients SRS/SRT was used as a boost after conventional radiotherapy and in 19 cases it was the only irradiation method applied. Patients were irradiated to total dose of 6-35 Gy and median total equivalent dose of 52 Gy. RESULTS: During median follow-up of 39 months, 4 patients died. One-, two- and five-year OS was 95%, 89% and 69%, respectively. In nine patients, progression of the disease was diagnosed during study period. One-, two- and five-year progression free survival (PFS) from the end of radiotherapy was 81%, 59% and 43%, respectively. Radiotherapy was well tolerated and only two patients in our group experienced moderate treatment-related toxicity. CONCLUSION: SRS/SRT alone or in combination with surgery is a safe and effective method of irradiation of patients with skull base chordomas. High EQD2 is necessary to achieve satisfactory treatment results.
Authors: Bowen Jiang; Anand Veeravagu; Marco Lee; Griffith R Harsh; Robert E Lieberson; Inderpreet Bhatti; Scott G Soltys; Iris C Gibbs; John R Adler; Steven D Chang Journal: J Clin Neurosci Date: 2012-06-20 Impact factor: 1.961
Authors: Darlene M Bugoci; Michael R Girvigian; Joseph C T Chen; Michael M Miller; Javad Rahimian Journal: Am J Clin Oncol Date: 2013-08 Impact factor: 2.339
Authors: E B Hug; L N Loredo; J D Slater; A DeVries; R I Grove; R A Schaefer; A E Rosenberg; J M Slater Journal: J Neurosurg Date: 1999-09 Impact factor: 5.115
Authors: Daniela Schulz-Ertner; Christian P Karger; Alexandra Feuerhake; Anna Nikoghosyan; Stephanie E Combs; Oliver Jäkel; Lutz Edler; Michael Scholz; Jürgen Debus Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-23 Impact factor: 7.038
Authors: Salvatore Chibbaro; Jan Frederick Cornelius; Sebastien Froelich; Leonardo Tigan; Pierre Kehrli; Christian Debry; Antonio Romano; Philippe Herman; Bernard George; Damien Bresson Journal: Neurosurg Rev Date: 2013-11-19 Impact factor: 3.042